Melanoma and Immunotherapy

Alexander M.M. Eggermont; Dirk Schadendorf

doi:10.1016/j.hoc.2009.03.009

Melanoma and Immunotherapy

Alexander M.M. Eggermont, Dirk Schadendorf

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

41 Citaten (Scopus)

Samenvatting

About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

Originele taal-2	Engels
Pagina's (van-tot)	547-564
Aantal pagina's	18
Tijdschrift	Hematology/Oncology Clinics of North America
Volume	23
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1016/j.hoc.2009.03.009
Status	Gepubliceerd - jun. 2009
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.hoc.2009.03.009

Citeer dit

@article{2668bccc29ed421da9152bd399a2c058,

title = "Melanoma and Immunotherapy",

abstract = "About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.",

keywords = "Antibodies, Cytokines, Immunotherapy, Melanoma, Review, Vaccines",

author = "Eggermont, {Alexander M.M.} and Dirk Schadendorf",

year = "2009",

month = jun,

doi = "10.1016/j.hoc.2009.03.009",

language = "English",

volume = "23",

pages = "547--564",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Melanoma and Immunotherapy

AU - Eggermont, Alexander M.M.

AU - Schadendorf, Dirk

PY - 2009/6

Y1 - 2009/6

N2 - About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

AB - About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

KW - Antibodies

KW - Cytokines

KW - Immunotherapy

KW - Melanoma

KW - Review

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=65649126818&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2009.03.009

DO - 10.1016/j.hoc.2009.03.009

M3 - Review article

C2 - 19464602

AN - SCOPUS:65649126818

SN - 0889-8588

VL - 23

SP - 547

EP - 564

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 3

ER -

Melanoma and Immunotherapy

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit